Apollomics GAAP EPS of -$4.04 (NASDAQ:APLM)
Apollomics reported a GAAP EPS of -$4.04 for the first half of 2026, with cash and cash equivalents of $1.0M as of June 30, 2026, according to the company.
How this was made
The 30-second read
Why it matters
The earnings miss and low cash balance may trigger short‑selling pressure and a decline in share price.
Market read
The report provides fresh earnings data for a small cap, offering a modest trading opportunity.
What to watch
Potential upcoming pipeline milestones not disclosed in this brief.
Background
Apollomics is a micro‑cap biotech company listed on NASDAQ under ticker APLM.
Ticker impact
Apollomics reported 1H GAAP EPS of -$4.04 and cash of $1.0M as of June 30, 2026.
likely pressure as the market prices in the loss and weak balance sheet
The disclosed loss and low cash position are material new facts for a micro‑cap, prompting a sell‑side bias.
Market effects
Limited impact beyond the biotech micro‑cap space.
Primarily affects US small‑cap investors.
Low global relevance.
Counterpoint
If the loss reflects a one‑time charge, the stock could be undervalued.
Key entities
- CompanyApollomics, Inc.
NASDAQ‑listed biotech reporting its first‑half results.
